Rodbard, H
Zhou H, Yamada Y, Tsukiyama K, et al
Any change of insulin should be made cautiously and only under medical supervision
Key differential aspects of the group of glucagon-like peptide-1 receptor agonist drugs There are several arGLP-1 s approved or under study for the use in DM2: exenatide (exenatide and exenatide LAR or weekly), liraglutide, lixisenatide, dulaglutide, semaglutide, albiglutide (withdrawn from the market), and efpeglenatide (in clinical development)
Exclusion criteria included polycystic ovarian syndrome (defined as female sex and age under 40 years at the time of first metformin prescription), immigration within the last 10 years, age over 95 years, an eGFR measurement below 30 mL/min/1.73 m 2 within the year before the index date, an ICD code indicating heart failure within the last 10 years (Table S2), missing prebaseline HbA1c data, an HbA1c level below 42 mmol/mol, or a diagnosis of gestational diabetes (DO244)
Gender-specific adverse event profiling A comprehensive gender-based subgroup analysis was conducted to evaluate differential adverse reaction patterns associated with GLP-1 receptor agonist and metformin combination therapy
